Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Multicenter, Randomized, Double-Blind Evaluation of the Efficacy and Safety of Oral GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder

NCT07115329 is registered in ClinicalTrials.gov with Syndeio Biosciences, Inc as lead sponsor.

NCT NCT07115329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07115329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Multicenter, Randomized, Double-Blind Evaluation of the Efficacy and Safety of Oral GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Lead sponsor
Syndeio Biosciences, Inc
Phase
Phase 2
Overall status
Recruiting
Start date
January 5, 2026
Completion date
June 30, 2028
Enrollment
164 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder